Arrowhead Acquires Novartis' RNAi Research and Development Portfolio
- Conference Call Today at
Key aspects of the acquisition include the following:
- Multiple patent families covering RNAi-trigger design rules and modifications that fall outside of key patents controlled by competitors, which the Company believes provides freedom to operate for any target and indication;
- Novel intracellular targeting ligands that enhance the activity of RNAi-triggers by targeting the RNA-induced silencing complex (RISC) more effectively and improving stability once RISC is loaded;
- An assignment of Novartis' license from Alnylam Pharmaceuticals granting Arrowhead access to Alnylam intellectual property, excluding delivery, for 30 gene targets chosen by Novartis;
- A pipeline of three candidates initiated by Novartis and for which Novartis has developed varying amounts of preclinical data.
"This is an important deal for us. Novartis has been working in the RNAi
field for over a decade and their developments in proprietary
oligonucleotide formatting and modifications are some of the best we've
seen. We anticipate this acquisition will provide us with substantially
expanded freedom to operate, proprietary technology that appears to
enhance the activity of RNAi triggers, access to non-delivery Alnylam
RNAi IP for 30 targets, and three programs that went through the
rigorous Novartis vetting process," said
Under the terms of the agreement, Arrowhead previously made a payment to
Conference Call and Webcast Details
To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 98554265. Investors may also access a live audio webcast of this conference call on the Company's website at http://ir.arrowheadresearch.com/events.cfm.
A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 7 days. The audio replay can be accessed by dialing 855-859-2056 (toll free from the US), or 404-537-3406 (for international callers) and entering Conference ID 98554265.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, actions of the
Matt Middleman, M.D., 212-845-4272
News Provided by Acquire Media